Multiple Sclerosis News Today

Multiple Sclerosis News Today is an online news platform focused on providing in-depth daily updates about Multiple Sclerosis (MS).

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#257289

United States

#95560

Health/Health Conditions and Concerns

#229

Traffic sources

Monthly visitors

Articles

3 progressive MS patients see lowered disability with CAR T-cell therapy

3 days ago | multiplesclerosisnewstoday.com | Marisa Wexler

A CAR T-cell therapy from Iaso Biotherapeutics was tolerated well and led to marked improvements in disability for three people with progressive forms of multiple sclerosis (MS), according to early data from a Phase 1 clinical trial. After a single dose of equecabtagene autoleucel, patients saw rapid and sustained benefits, the company announced.
Outcomes in MS may be influenced by fat composition in ketogenic diet: Study

5 days ago | multiplesclerosisnewstoday.com | Steve Bryson

A ketogenic diet — a very low-carbohydrate, high-fat diet — rich in long-chain, saturated fatty acids like those in butter and fatty red meat didn’t reduce optic nerve damage in a mouse model of multiple sclerosis (MS), a study shows. Instead, feeding mice this type of diet before the onset of their disease modestly worsened certain visual impairments.
Foralumab nasal spray trial starts dosing patients at Weill Cornell

1 week ago | multiplesclerosisnewstoday.com | Andrea Lobo

A multicenter Phase 2a clinical trial testing foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS) has begun dosing patients at Weill Cornell Medicine Multiple Sclerosis Center in New York. The Phase 2a study (NCT06292923) is assessing the safety and efficacy of Tiziana Life Sciences‘ therapy, and aims to enroll up to 54 participants. Dosing began in late 2023 at Brigham and Women’s Hospital in Boston.
Brain growth may compensate for damage in benign MS: Study

1 week ago | multiplesclerosisnewstoday.com | Marisa Wexler

In people with benign relapsing-remitting multiple sclerosis (RRMS) who have minimal disease activity, there is a loss of overall brain tissue but specific parts of the brain may grow to help compensate for the damage, a new study indicates. The study, “AI-driven MRI analysis reveals brain atrophy patterns in benign relapsing-remitting multiple sclerosis,” was published in Frontiers in Neurology.
Age at MS onset linked to long-term physical, mental health: Study

1 week ago | multiplesclerosisnewstoday.com | Margarida Maia

People who develop multiple sclerosis (MS) at a younger age tend to consistently have better physical health but worse mental health than those diagnosed later, a study found. While physical health declined in the long term for all age groups, and mental health increased, the differences between groups were sustained over time, which the researchers said highlighted the need for age-tailored care.
Gender-affirming hormone therapy may affect MS disease activity

1 week ago | multiplesclerosisnewstoday.com | Marisa Wexler

Hormone therapies used in gender-affirming care for transgender people may affect disease activity in multiple sclerosis (MS), a small new study reports, although its researchers cautioned that more research is are needed to more comprehensively assess its impact in MS. The study, “Gender-affirming interventions and prognosis in multiple sclerosis,” was published in Multiple Sclerosis Journal.
Gum disease may accelerate MS progression, mouse study suggests

1 week ago | multiplesclerosisnewstoday.com | Steve Bryson

Gum disease caused by the bacterium Porphyromonas gingivalis (Pg) is associated with worse multiple sclerosis (MS) in a mouse model of the disease, a study shows. Infection with Pg directly or indirectly boosted pro-inflammatory pathways in immune cells in the spleen, where they’re produced, thereby aggravating MS. These effects were also associated with low oxygen conditions (hypoxia) and the activation of hypoxia-inducible factor 1 alpha (HIF-1-alpha).
Experimental MS therapy safely repairs myelin sheath in animals

1 week ago | multiplesclerosisnewstoday.com | Steve Bryson

An experimental medicine, 2-D08, boosts motor function in mice and primate models of multiple sclerosis (MS) by repairing the myelin sheath, the protective coating on nerve fibers that’s damaged in people with the neurodegenerative condition, a study showed. 2-D08 also outperformed the approved therapy dalfampridine, sold as Ampyra in the U.S., in its ability to repair myelin without inducing seizures, a known fampridine side effect.
Aetna Healthcare agrees to reimburse PoNS device for MS patients

2 weeks ago | multiplesclerosisnewstoday.com | Andrea Lobo

Aetna Healthcare has agreed to reimburse Helius Medical Technologies’ PoNS device, short for Portable Neuromodulation Stimulator, which uses electrical stimulation to improve walking in people with multiple sclerosis (MS). The policy covers PoNS at an out-of-network negotiated price of $18,350, making Aetna, one of the largest private health insurers in the U.S., the third major one to approve reimbursement for the device, after Anthem and United Healthcare.
Children with MS show signs of accelerated biological aging

2 weeks ago | multiplesclerosisnewstoday.com | Marisa Wexler

Children with pediatric-onset multiple sclerosis (POMS) experience biological aging at a faster rate than children without the disease, a study shows. “We found evidence that children living with MS experience accelerated biological aging,” Jennifer Graves, MD, PhD, senior author of the study at the University of California, San Diego, said in a university news story. The study, “Epigenetic Aging in Pediatric-Onset Multiple Sclerosis,” was published in Neurology.